148 related articles for article (PubMed ID: 38787503)
1. ELF3 plays an important role in defining TRAIL sensitivity in breast cancer by modulating the expression of decoy receptor 2 (DCR2).
Ghosal N; Tapadar P; Biswas D; Pal R
Mol Biol Rep; 2024 May; 51(1):671. PubMed ID: 38787503
[TBL] [Abstract][Full Text] [Related]
2. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.
Sanlioglu AD; Dirice E; Aydin C; Erin N; Koksoy S; Sanlioglu S
BMC Cancer; 2005 May; 5():54. PubMed ID: 15916713
[TBL] [Abstract][Full Text] [Related]
3. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
Jang JY; Jeon YK; Choi Y; Kim CW
Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
[TBL] [Abstract][Full Text] [Related]
4. β-catenin is regulated by USP9x and mediates resistance to TRAIL-induced apoptosis in breast cancer.
Ouyang W; Zhang S; Yang B; Yang C; Zhang J; Zhou F; Xie C
Oncol Rep; 2016 Feb; 35(2):717-24. PubMed ID: 26717875
[TBL] [Abstract][Full Text] [Related]
5. Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.
O'Leary L; van der Sloot AM; Reis CR; Deegan S; Ryan AE; Dhami SP; Murillo LS; Cool RH; Correa de Sampaio P; Thompson K; Murphy G; Quax WJ; Serrano L; Samali A; Szegezdi E
Oncogene; 2016 Mar; 35(10):1261-70. PubMed ID: 26050621
[TBL] [Abstract][Full Text] [Related]
6. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
7. CDH1 overexpression sensitizes TRAIL resistant breast cancer cells towards rhTRAIL induced apoptosis.
Tapadar P; Pal A; Ghosal N; Kumar B; Paul T; Biswas N; Pal R
Mol Biol Rep; 2023 Sep; 50(9):7283-7294. PubMed ID: 37422537
[TBL] [Abstract][Full Text] [Related]
8. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
Shlyakhtina Y; Pavet V; Gronemeyer H
Cell Death Dis; 2017 Aug; 8(8):e3025. PubMed ID: 29048428
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S
Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479
[TBL] [Abstract][Full Text] [Related]
10. Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
Soto-Gamez A; Wang Y; Zhou X; Seras L; Quax W; Demaria M
Cancer Lett; 2022 Jan; 525():67-75. PubMed ID: 34728311
[TBL] [Abstract][Full Text] [Related]
11. The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer.
Zhang N; Wang X; Huo Q; Li X; Wang H; Schneider P; Hu G; Yang Q
J Biol Chem; 2013 Mar; 288(13):9396-407. PubMed ID: 23408429
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
15. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells.
Aydin C; Sanlioglu AD; Karacay B; Ozbilim G; Dertsiz L; Ozbudak O; Akdis CA; Sanlioglu S
Hum Gene Ther; 2007 Jan; 18(1):39-50. PubMed ID: 17187448
[TBL] [Abstract][Full Text] [Related]
16. Ischemic Preconditioning Upregulates Decoy Receptors to Protect SH-SY5Y Cells from OGD Induced Cellular Damage by Inhibiting TRAIL Pathway and Agitating PI3K/Akt Pathway.
Jin W; Xu W; Zhang X; Ren CC
Mol Neurobiol; 2020 Sep; 57(9):3658-3670. PubMed ID: 32564286
[TBL] [Abstract][Full Text] [Related]
17. A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells.
Gajulapalli VN; Samanthapudi VS; Pulaganti M; Khumukcham SS; Malisetty VL; Guruprasad L; Chitta SK; Manavathi B
Biochem J; 2016 Apr; 473(8):1047-61. PubMed ID: 26920025
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
19. The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells.
Zhu H; Huang M; Ren D; He J; Zhao F; Yi C; Huang Y
Biomed Res Int; 2013; 2013():293874. PubMed ID: 24324958
[TBL] [Abstract][Full Text] [Related]
20. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
